IL10 and diabetes mellitus: Collectively, we identified that the injection of IL-10-treated SVFs is capable of mitigating diabetes-induced adipose inflammation, liver gluconeogenesis, and insulin resistance, which may be mediated through an increase in Tregs in the adipose tissue.